ストックスクリーナーアプリを入手
191.26
1.49%
2.81
アフターアワーズ：
191.26
前日終値:
$188.45
開ける：
$191.53
24時間の取引高:
1.22M
Relative Volume:
0.91
時価総額：
$27.74B
収益：
$5.54B
当期純損益:
$1.52B
株価収益率:
18.44
EPS:
10.3734
ネットキャッシュフロー:
$1.74B
1週間 パフォーマンス:
-1.38%
1か月 パフォーマンス:
-8.07%
6か月 パフォーマンス:
-21.81%
1年 パフォーマンス:
-24.85%
1日の値動き範囲:
$190.16
$193.85
1週間の範囲:
$184.65
$193.85
52週間の値動き範囲:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Compare RMD vs ISRG, BDX, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
191.26 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
403.18 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.92 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.12 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.30 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | 開始されました | JP Morgan | Overweight |
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Resmed Inc (RMD) Institutional Confidence - TradingKey
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Should you continue to hold Resmed stock in your portfolio? - MSN
Should I buy CSL and ResMed shares right now? - The Motley Fool Australia
ResMed downgraded at Morgan Stanley on Philips re-entry and GLP-1 headwinds - MSN
ResMed edges higher after mixed analyst signals, shares trade near recent targets - AD HOC NEWS
Could ResMed (NYSE:RMD) Be Entering a New Chapter in Sleep Care? - Kalkine Media
ResMed trims KeyBanc price target, analyst views on the shares stay constructive - AD HOC NEWS
KeyBanc Adjusts Price Target on ResMed to $266 From $290, Maintains Overweight Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Unveiling A 39% Potential Upside Amidst Solid Growth - DirectorsTalk Interviews
Resmed Inc (RMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Is ResMed (NYSE:RMD) Market Reset Creating New Interest? - Kalkine Media
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) was downgraded to a Hold Rating at Morgan Stanley - The Globe and Mail
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Resmed Inc (RMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
Is ResMed stock underperforming the Dow? - MSN
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos - The Globe and Mail
Resmed Inc (RMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Top ResMed (RMD) Competitors 2026 - MarketBeat
ResMed Loses Bull as Margin Outlook Moderates -- Market Talk - Moomoo
Resmed Closes Acquisition of Noctrix Health - Moomoo
ResMed Inc (RMD) Stock Down 3.9% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
ResMed (RMD) Faces Downgrade Amid Market Concerns - GuruFocus
ResMed Shares Fall After Morgan Stanley Downgrade - Moomoo
Lobbying Update: $40,000 of RESMED CORP. lobbying was just disclosed - Quiver Quantitative
ResMed Inc. Stock 12‑Month Price Target Cut to $277.74, Implies 43% Upside - TradingView
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ResMed stock downgraded at Morgan Stanley (RMD:NYSE) - Seeking Alpha
Resmed Completes Acquisition of Noctrix Health - San Diego Business Journal
Morgan Stanley Downgrades ResMed(RMD.US) to Hold Rating, Cuts Target Price to $230 - Moomoo
Morgan Stanley downgrades ResMed stock rating on margin concerns - Investing.com
Morgan Stanley Downgrades ResMed to Equalweight From Overweight, Adjusts PT to $230 From $286 - marketscreener.com
Morgan Stanley downgrades ResMed stock rating on margin concerns By Investing.com - Investing.com UK
Analyst recommendations: Block, Resmed, Applied Materials, Ge Vernova, Intel… - marketscreener.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
ResMed Is Maintained at Buy by Citigroup - Moomoo
Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? - MSN
Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Exploring a Potential 38.93% Upside in the Healthcare Innovator - DirectorsTalk Interviews
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
Landscape Capital Management L.L.C. Sells 32,899 Shares of ResMed Inc. $RMD - MarketBeat
Will GLP-1 Pressure and Insider Selling Change ResMed's (RMD) Long-Term Sleep-Health Narrative - Sahm
ResMed added as new short idea at Hedgeye - MSN
ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure - AD HOC NEWS
Milford Funds Ltd. Makes New $28.42 Million Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Nutshell Asset Management Ltd's ResMed Inc(RMD) Holding History - GuruFocus
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
1.70%
大文字化:
|
ボリューム (24 時間):